U.S. Markets closed

IntriCon Reports First Quarter 2020 Results

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ARDEN HILLS, Minn., May 19, 2020 (GLOBE NEWSWIRE) -- IntriCon Corporation (IIN), a designer, developer and manufacturer of miniature interventional, implantable and body-worn medical devices, today announced financial results for its first quarter ended March 31, 2020.

Commenting on the recently completed quarter, Mark Gorder, president and chief executive officer of IntriCon commented, “The impact of the COVID-19 pandemic has been extraordinary. At IntriCon, we quickly responded by shifting our operations to best ensure the health of our employees and their families, while maintaining operation-critical processes essential to supporting our customers, their patients, and our on-going business.

“During this period we also completed a number of actions that we believe will significantly transform our organization and best position us for long term growth by focusing on what we do best - delivering complex micro-miniature medical devices that require specialized design expertise and high production volumes. These actions included the acquisition of Emerald Medical Services, which immediately expands our medical market opportunity and diversifies our customer base. Following our decision last quarter to discontinue direct-to-consumer initiatives in the hearing health market, we accelerated a restructuring within our Hearing Help Express business to further focus resources on partnership opportunities and substantially reduce the associated losses. We also took actions to restructure other areas of our global workforce to further streamline our resources to best align with current priorities,” continued Gorder.

First Quarter Financial Highlights:

  • Revenue of $21.5 million

    • Revenue from largest medical customer declined 21.2% year-over-year

  • Gross margin of 21.3%

  • Net loss per diluted share of $0.22 versus net income of $0.08 per diluted share in the prior year period

  • Enacted measures designed to ensure business continuity, reduce operating expense, and preserve cash as the ongoing COVID-19 pandemic impacts revenue

Recent Operational Highlights:

  • Acquired Emerald Medical Services Pte. Ltd., a privately held provider of joint development medical device manufacturing services for complex catheter applications

  • Completed a global net workforce reduction of 25 positions resulting in an annual, net cost savings of approximately $1.5 million

  • Accelerated the Hearing Help Express restructuring to focus on partnerships in the hearing health market, resulting in an approximately $2.0 million reduction in consumer advertising expense in 2020 as compared to 2019 and a workforce reduction resulting in an annual, net cost savings of approximately $900,000

  • Enhanced our leadership team with two key additions with extensive organization development expertise

    • Heather Rider joined IntriCon’s board of directors in March

    • Sara Hill joined the company’s executive team as Chief Human Resource Officer

“I’m proud of the substantial progress the IntriCon team has made on the priorities we established for the year, including continuing to meet the volume demands of Medtronic’s diabetes business; accelerating market and customer diversification; pursuing partnerships in hearing health; and adjusting our organizational structure to address opportunities in high growth markets,” concluded Gorder.

First Quarter 2020 Financial Results
For the 2020 first quarter, the company reported net revenue of $21.5 million versus $29.6 million in the comparable prior-year period. Net revenues in the quarter included a one-time charge of $1.2 million reflecting a change in the company’s revenue recognition methodology for certain medical customers.

Revenue in IntriCon’s Medical business in the first quarter of 2020 was $16.4 million, a decrease from $20.8 million in the comparable prior-year period. The year over year decline was driven primarily by the COVID-19 impact on diabetes, one-time revenue recognition adjustment, partially offset by medical coil demand.

Hearing Health revenue was $3.9 million in the first quarter of 2020 compared to $7.0 million in the prior-year first quarter. The revenue decline during the first quarter was largely attributed to the absence of hi HealthInnovations revenue and COVID-19 impact on the Legacy hearing health channel.

Gross margin in the first quarter of 2020 was 21.3%, down from 28.9% in the prior-year first quarter. Gross margins were constrained by excess manufacturing capacity.

Operating expenses for the first quarter were $6.6 million, compared to $7.5 million in the comparable prior-year period. The decrease stemmed from a substantial reduction in advertising expense in its direct-to-end-consumer business.

The company posted a net loss of approximately $2.0 million or $0.22 per diluted share in the first quarter of 2020, versus net income of approximately $775,000 or $0.08 per diluted share, for the 2019 first quarter.

2020 Guidance
IntriCon withdrew its previously announced annual guidance for 2020 on April 7, 2020. Given the uncertain scope and duration of the COVID-19 pandemic, the company remains unable to accurately estimate the impact of the pandemic on its future operations and financial results.

Conference Call
IntriCon’s management team will hold a conference call today, May 19, 2020, beginning at 4:00 p.m. CT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 866-795-7248 for domestic callers or 470-495-9160 for international callers, using conference ID: 6561768. A live and archived webcast will be available on the “Investors” sections of the company’s website at: www.IntriCon.com.

Forward-Looking Statements
Statements made in this release and in IntriCon’s other public filings and releases that are not historical facts or that include forward-looking terminology, including estimates of future results, the impact of the Emerald acquisition, statements regarding the estimated costs and expenses of the restructuring and estimated annual expense savings, are “forward-looking statements” within the meaning of the Private Securities Exchange Litigation Reform Act of 1934, as amended 1995. These forward-looking statements may be affected by known and unknown risks, uncertainties and other factors that are beyond IntriCon’s control, including without limitation, the impacts of the COVID-19 pandemic and measures taken in response, the risks associated with the Emerald acquisition, the actual number of employee headcount reductions in our strategic restructuring, the results of our lease negotiations, actual cash expenditures that may be made by the company in connection with the reduction in force and the amount, use and impact of any savings generated by the reduction in force and restructuring, and may cause IntriCon’s actual results, performance or achievements to differ materially from the results, performance and achievements expressed or implied in the forward-looking statements. These risks, uncertainties and other factors are detailed from time to time in the company’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2019 and the company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission on May 8, 2020 and May 19, 2020. The company disclaims any intent or obligation to publicly update or revise any forward-looking statements, regardless of whether new information becomes available, future developments occur or otherwise.

About IntriCon Corporation
Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature interventional, implantable and body-worn devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better-connected devices. IntriCon has facilities in the United States, Asia, and Europe. The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market. For more information about IntriCon, visit www.intricon.com.

Investor Contact
Leigh Salvo
(415) 937-5404
investorrelations@intricon.com

INTRICON CORPORATION
MARKET REVENUE
(Unaudited)

FIRST QUARTER

($ in 000's)

2020

2019

Change

Medical

$

16,358

$

20,793

-21.3

%

Diabetes

13,530

17,164

-21.2

%

Other Medical

2,828

3,629

-22.1

%

Hearing Health

3,881

7,010

-44.6

%

Value Based Direct-to-End-Consumer

1,173

1,630

-28.0

%

Value Based Indirect-to-End-Consumer

744

2,577

-71.1

%

Legacy OEM

1,964

2,803

-29.9

%

Professional Audio Communications

1,264

1,767

-28.5

%

Total

$

21,503

$

29,570

-27.3

%

INTRICON CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Amounts)

Three Months Ended

(unaudited)

March 31,

March 31,

2020

2019

Revenue, net

$

21,503

$

29,570

Cost of goods sold

16,931

21,012

Gross profit

4,572

8,558

Operating expenses:

Sales and marketing

1,993

3,389

General and administrative

3,416

3,186

Research and development

1,201

965

Total operating expenses

6,610

7,540

Operating (loss) income

(2,038)

1,018

Interest income, net

184

215

Other expense, net

(107)

(134)

(Loss) income from continuing operations before income taxes and discontinued operations

(1,961)

1,099

Income tax expense

18

131

(Loss) income from continuing operations before discontinued operations

(1,979)

968

Loss from discontinued operations (Note 3)

-

(193)

Net (loss) income

$

(1,979)

$

775

Basic (loss) income per share:

Continuing operations

$

(0.22)

$

0.11

Discontinued operations

-

(0.02)

Net (loss) income per share:

$

(0.22)

$

0.09

Diluted (loss) income per share:

Continuing operations

$

(0.22)

$

0.10

Discontinued operations

-

(0.02)

Net (loss) income per share:

$

(0.22)

$

0.08

Average shares outstanding:

Basic

8,813

8,705

Diluted

8,813

9,382

INTRICON CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEET
(In Thousands, Except Per Share Amounts)

(unaudited)

March 31,

December 31,

2020

2019

Current assets:

Cash and cash equivalents

$

15,177

$

8,523

Restricted cash

616

639

Short-term investment securities

16,889

23,451

Accounts receivable, less allowance for doubtful accounts of $331 at March 31, 2020 and $325 at December 31, 2019

8,241

8,993

Inventories

19,115

16,377

Contract assets

10,079

10,237

Other current assets

1,426

1,975

Current assets of discontinued operations

-

80

Total current assets

71,543

70,275

Machinery and equipment

42,944

41,073

Less: Accumulated depreciation

28,213

27,522

Net machinery and equipment

14,731

13,551

Goodwill

9,551

9,551

Operating lease right-of-use assets, net

3,862

4,372

Investment in partnerships

750

1,160

Long-term investment securities

5,379

8,629

Other assets, net

5,902

6,055

Total assets

$

111,718

$

113,593

Current liabilities:

Current financing leases

$

88

$

101

Current operating leases

1,605

1,729

Accounts payable

10,392

9,876

Accrued salaries, wages and commissions

2,736

2,274

Other accrued liabilities

2,474

2,869

Liabilities of discontinued operations

-

77

Total current liabilities

17,295

16,926

Noncurrent financing leases

15

30

Noncurrent operating leases

2,503

2,937

Other postretirement benefit obligations

371

382

Accrued pension liabilities

651

655

Other long-term liabilities

2,106

2,171

Total liabilities

22,941

23,101

Commitments and contingencies (Note 15)

Shareholders’ equity:

Common stock, $1.00 par value per share; 20,000 shares authorized; 8,819 and 8,781 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

8,819

8,781

Additional paid-in capital

86,978

86,770

Accumulated deficit

(6,265)

(4,286)

Accumulated other comprehensive loss

(502)

(520)

Total shareholders' equity

89,030

90,745

Non-controlling interest

(253)

(253)

Total equity

88,777

90,492

Total liabilities and equity

$

111,718

$

113,593